诺和诺德美股盘前涨超2%，此前一度跌近3%，报道称美国拟扩大减肥药医保覆盖范围。

Core Viewpoint - Novo Nordisk's stock rose over 2% in pre-market trading after previously experiencing a nearly 3% decline, following reports that the U.S. plans to expand insurance coverage for weight loss medications [1] Company Summary - Novo Nordisk's stock performance reflects market reactions to potential policy changes regarding weight loss medication coverage in the U.S. [1] Industry Summary - The pharmaceutical industry, particularly in the weight loss medication segment, may see increased demand and market growth due to expanded insurance coverage [1]